Shares of Intrexon Corp. (NYSE:XON) traded down 3.4% during mid-day trading on Thursday . The company traded as low as $24.33 and last traded at $24.69, with a volume of 517,739 shares traded. The stock had previously closed at $25.57.

A number of analysts have recently issued reports on the company. Vetr lowered Intrexon Corp. from a “sell” rating to a “strong sell” rating and set a $22.26 price target on the stock. in a research note on Wednesday. Zacks Investment Research raised Intrexon Corp. from a “hold” rating to a “buy” rating and set a $29.00 price target on the stock in a research note on Tuesday, July 19th. JMP Securities reaffirmed a “buy” rating on shares of Intrexon Corp. in a research note on Sunday, July 17th. Wunderlich reissued a “buy” rating and set a $50.00 price objective on shares of Intrexon Corp. in a research note on Thursday, July 7th. Finally, Stifel Nicolaus reissued a “buy” rating and set a $57.00 price objective on shares of Intrexon Corp. in a research note on Wednesday, June 29th. Two equities research analysts have rated the stock with a sell rating, three have given a hold rating and six have given a buy rating to the company’s stock. Intrexon Corp. has a consensus rating of “Hold” and an average target price of $47.23.

The company’s 50 day moving average price is $24.97 and its 200-day moving average price is $29.57. The firm’s market cap is $2.92 billion.

Intrexon Corp. (NYSE:XON) last released its quarterly earnings data on Tuesday, May 10th. The company reported ($0.55) earnings per share for the quarter, missing the consensus estimate of ($0.20) by $0.35. The company earned $43.40 million during the quarter, compared to analysts’ expectations of $46.26 million. Intrexon Corp.’s quarterly revenue was up 28.4% compared to the same quarter last year. During the same period in the prior year, the firm earned $0.25 earnings per share. Analysts expect that Intrexon Corp. will post ($1.32) EPS for the current fiscal year.

In other news, CEO Randal J. Kirk acquired 41,830 shares of the company’s stock in a transaction that occurred on Friday, May 13th. The stock was purchased at an average cost of $23.92 per share, with a total value of $1,000,573.60. The acquisition was disclosed in a document filed with the SEC, which is available through this link.

A number of institutional investors have recently added to or reduced their stakes in XON. State of Wisconsin Investment Board increased its position in Intrexon Corp. by 2.5% in the fourth quarter. State of Wisconsin Investment Board now owns 35,410 shares of the company’s stock valued at $1,068,000 after buying an additional 880 shares during the last quarter. Bank of Montreal Can increased its position in Intrexon Corp. by 16.8% in the fourth quarter. Bank of Montreal Can now owns 40,010 shares of the company’s stock valued at $1,207,000 after buying an additional 5,742 shares during the last quarter. Rhumbline Advisers increased its position in Intrexon Corp. by 6.7% in the fourth quarter. Rhumbline Advisers now owns 46,016 shares of the company’s stock valued at $1,387,000 after buying an additional 2,890 shares during the last quarter. State Board of Administration of Florida Retirement System increased its position in Intrexon Corp. by 15.4% in the fourth quarter. State Board of Administration of Florida Retirement System now owns 50,351 shares of the company’s stock valued at $1,518,000 after buying an additional 6,705 shares during the last quarter. Finally, Swiss National Bank increased its position in Intrexon Corp. by 3.8% in the fourth quarter. Swiss National Bank now owns 62,500 shares of the company’s stock valued at $1,884,000 after buying an additional 2,300 shares during the last quarter.

Intrexon Corporation (Intrexon) forms collaborations to create biologically based products and processes using synthetic biology. The Company designs, builds and regulates gene programs, which are deoxyribonucleic acid (DNA) sequences that consist of genetic components. The Company’s synthetic biology capabilities include the ability to control the amount, location and modification of biological molecules to control the function and output of living cells and optimize for desired results at an industrial scale.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.